A committee of scientific advisors from the Centers for Disease Control and Prevention voted Thursday Pfizer-BioNtech recommend booster dose of coronavirus vaccine For many Americans who were fully vaccinated with the same vaccine. The panel advised that booster shots Go to older Americans and people with certain medical conditions, but exclude those at risk because of their jobs.
But the panel was not asked to decide whether people who got the Moderna and Johnson & Johnson vaccines should get the Pfizer booster. The Food and Drug Administration is reviewing data for the Moderna booster, but has not received an application from Johnson & Johnson. booster Its commentary.
Many experts nonetheless supported the mix-and-match strategy, and indicated that they would revisit the issue as new data emerged.
Advisors wrestled with the practicality of supporting Pfizer’s vaccine booster shot, but not the other two. Recipients of those vaccines may be asked to wait if evidence suggests they need boosters, he said.
“I don’t understand how, later this afternoon, we can say to people 65 and older, ‘You’re at risk of serious illness and death, but only half of you can protect yourself. ,” Doctor. Sarah Long, a pediatrician and infectious disease specialist at Drexel University College of Medicine in Pennsylvania.
“It might be the right thing to do,” she said. “It just doesn’t sound like a good public health policy.”
Some experts suggested Wednesday that it may be better to recommend any booster shots until recipients of all three vaccines qualify for them.
Moderna’s authorization could come in a few days or weeks. The company has applied for authorization of a half-dose booster given in the first two shots, delaying the FDA’s deliberations.
Federal regulators have indicated that there was insufficient evidence to combine the first shots of Moderna Vaccine with the Pfizer booster, or vice versa.